companies / poplartx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-12 json
| total_raised | 50,000,00050.0M | ○ |
|---|---|---|
| founded | 2024 | |
| hq | San Francisco | |
| industry | unknown | |
| stage | series-a |
Poplar Therapeutics develops pharmaceutical treatments focused on new anti-IgE medicines to help patients manage allergic conditions. Its audience includes patients with anti-IgE-treatable conditions, healthcare professionals, and investors. Its edge is targeting therapies that aim to push beyond the limits of existing anti-IgE treatments.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-01-07 | series-a | 50,000,00050.0M | null | ○ |
astra 4.12.0, cloudflare, cloudflare bot management, doubleclick floodlight, google analytics, google tag manager, gravity forms 2.10.3, gutenberg, http/3, mysql, php, spectra 2.19.17
| fact | status | src |
|---|---|---|
| Series A, $50.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |